Heterocyclic Compounds
The Identification of Clinical Candidate SB-480848 (I): A Potent Inhibitor of Lipoprotein-Associated Phospholipase A2.
Stephen A. Smith,
Stephen A. Smith
Med. Res. Cent., Glaxo Wellcome Res. Dev. Ltd., Stevenage, Hertfordshire SG1 2NY, UK
Search for more papers by this author et al. et al.,
et al. et al.
Med. Res. Cent., Glaxo Wellcome Res. Dev. Ltd., Stevenage, Hertfordshire SG1 2NY, UK
Search for more papers by this author
Stephen A. Smith,
Stephen A. Smith
Med. Res. Cent., Glaxo Wellcome Res. Dev. Ltd., Stevenage, Hertfordshire SG1 2NY, UK
Search for more papers by this author et al. et al.,
et al. et al.
Med. Res. Cent., Glaxo Wellcome Res. Dev. Ltd., Stevenage, Hertfordshire SG1 2NY, UK
Search for more papers by this author
First published: 09 July 2003
No abstract is available for this article.
-
Stephen A. Smith,
et al. et al.,
The Identification of Clinical Candidate SB-480848 (I): A Potent Inhibitor of Lipoprotein-Associated Phospholipase A2.,
Bioorg. Med. Chem. Lett.,
2003,
13,
1067–1070.
